APOB and atherosclerosis: Because of its ability to quantify the burden of atherogenic lipoprotein particle number more completely and accurately than non-HDL-C, multiple studies suggest that apoB is a superior marker of ASCVD risk, particularly in the 8–20% of people who have higher or lower than average apoB levels for a given non-HDL-C level (8).